Introduction Poor or inconsistent adherence to daily oral pre-exposure prophylaxis (PrEP)
has emerged as a key barrier to effective HIV prevention. The advent of potent long-acting …

Hydrogel-forming microarray patches (HF-MAPs) offer minimally invasive, pain-free and
prolonged drug delivery. These devices are designed to be self-administered and self …

Innovations in the field of long-acting injectable drug development are increasingly being
reported. More advanced in vitro and in vivo characterization can improve our …

Introduction Young African women bear a disproportionately high risk for HIV acquisition.
HIV technologies that empower women to protect themselves are needed. Safe, potent …

Subcutaneous injection is a commonly used route of drug administration for both small
molecules and biologics. To facilitate the development of new subcutaneously administered …

Complex injectable drug products (CIDPs) have often been developed to modulate the
pharmacokinetics along with efficacy for therapeutic agents used for remediation of chronic …

Developing long-acting products and formulations for infectious diseases is a nontrivial
undertaking that is frequently classified as high risk and low reward by the pharmaceutical …

Purpose Long-acting formulations of the potent antiretroviral prodrug tenofovir alafenamide
(TAF) hold potential as biomedical HIV prevention modalities. Here, we present a rigorous …

Subcutaneously administered drugs are growing in popularity for both large and small
molecule drugs. However, development of these systems–particularly generics–is slowed …

Tenofovir alafenamide (TAF) is a BCS Class III compound and an oral pro-drug of Tenofovir
(TFV) with limited oral bioavailability. The bioavailability of the oral intake increases with …